|1.||Ohbuchi, H: 1 article (03/2009)|
|2.||Hirota, K: 1 article (03/2009)|
|3.||Tani, S: 1 article (03/2009)|
|4.||Hagiwara, S: 1 article (03/2009)|
|5.||Kasuya, H: 1 article (03/2009)|
|6.||Tanaka, N: 1 article (03/2009)|
|7.||Nakamura, S: 1 article (03/2009)|
|8.||Iwabuchi, S: 1 article (03/2009)|
01/01/1987 - "When FUR was coadministered with ANEUR, mean tumor weight was 91% less than that of the untreated controls, showing that ANEUR, the potent URPase inhibitor, increases the antitumor effect of FUR."
01/01/1987 - "There was no significant difference in mean tumor weight on day 10 between control animals and animals treated with FUR (5 mg/kg/day for 3 days) or ANEUR (280 mg/kg/day for 3 days). "
04/01/1990 - "Whereas ANEUR annihilated the antitumor activity of 5-fluoro-2'-deoxyuridine (FUdR) and 5'-deoxy-5-fluorouridine (DFUR) in the murine adenocarcinoma 755 system, it did not alter the antitumor activity of FUdR in the human adenocarcinoma LS174T system. "
04/01/1990 - "2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice. "